With a landmark $277 million raise, Element Biosciences is scaling its AVITI™ platform and diving deep into multi-omics—reshaping how researchers decode biology across DNA, RNA, and proteins.
A Funding Milestone That Redefines the Sequencing Landscape
On November 6, 2024, Element Biosciences announced a $277 million Series D financing round, one of the largest private biotech raises of the year. The San Diego-based company, known for its AVITI™ sequencing system, is now setting its sights on multi-omics integration—a frontier that promises to transform how researchers study biology, disease, and drug response.
The round was led by existing investors with participation from new strategic partners, including global life sciences firms and institutional funds. The capital will be used to scale manufacturing, expand global distribution, and accelerate the development of new reagent kits for transcriptomics, epigenomics, and proteomics.
Element’s AVITI™ platform has already gained traction for its affordability, modularity, and open chemistry. Now, the company is positioning itself to become a central player in the multi-omics revolution, where DNA, RNA, and protein data converge to unlock deeper biological insights.
AVITI™ Evolves: From Genomics to Multi-Omics
Element’s AVITI™ system disrupted the sequencing market by offering:
But the company’s ambitions go far beyond DNA. With the Series D funding, Element is developing new workflows that allow researchers to analyse multiple molecular layers from a single sample. This includes:
By integrating these data types, scientists can build more complete models of cellular behaviour—critical for understanding complex diseases like cancer, neurodegeneration, and autoimmune disorders.
Why Multi-Omics Matters: From Discovery to Diagnostics
Multi-omics is more than a buzzword—it’s a paradigm shift. Traditional genomics tells us what might happen; multi-omics tells us what’s actually happening. This layered approach enables:
Element’s platform aims to simplify this complexity by offering integrated workflows, cloud-based analytics, and AI-driven interpretation tools. The goal is to move researchers from raw data to actionable insight—faster and more affordably than ever before.
Scaling Up: Global Reach and Strategic Partnerships
With its new funding, Element plans to:
The company is also investing in cloud infrastructure and machine learning algorithms to help users interpret multi-omics data in real time. This will be especially valuable for clinical researchers and diagnostic labs seeking to translate molecular data into patient care.
Looking Ahead: The Future of Biological Insight
Element Biosciences’ $277M raise is more than a financial milestone—it’s a signal that the future of biotech lies in integration, accessibility, and precision. As sequencing becomes more democratized and multi-omics tools become mainstream, expect a surge in discoveries that reshape our understanding of health and disease.
Keep in touch with our news & offers
